Increasing competition in the pharmaceutical industry through generic drugs could help curb rising drug costs, senators suggested Thursday at a Health, Education, Labor and Pensions Committee hearing. A Food and Drug Administration official said the agency has made significant progress in working through a backlog of generic drug applications.
It’s a common theme that lawmakers have brought up time and time again as prescription drug costs have become a hot political issue. The committee was reviewing the Generic Drug User Fee Amendment, which is up for reauthorization in 2017. The statute has reshaped how generic drugs are approved since it was first passed three years ago.
Read Full Article »